



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 473/40, C07H 19/20	A1	(11) International Publication Number: WO 92/09604 (43) International Publication Date: 11 June 1992 (11.06.92)
(21) International Application Number: PCT/US91/08838 (22) International Filing Date: 29 November 1991 (29.11.91) (30) Priority data: 620,236 29 November 1990 (29.11.90) US (71) Applicant: BERLEX BIOSCIENCES, INC. [US/US]; 110 E. Hanover Avenue, Cedar Knolls, NJ 07927 (US). (72) Inventors: BAUMAN, John, C. ; 2465 Shoreline Drive, #214, Alameda, CA 94501 (US). WIRSCHING, Randolph, C. ; 3364 Marina Avenue, Livermore, CA 94550 (US). (74) Agents: ZELANO, Anthony, J. et al.; Millen, White & Zelano, Arlington Courthouse Plaza 1, Suite 1201, 2200 Clarendon Boulevard, Arlington, VA 22201 (US).		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: 6-AZIDO-2-FLUOROPURINE (57) Abstract <p>This invention pertains to novel methods of synthesizing fludarabine, fludarabine phosphate and related nucleoside pharmacologic agents utilizing 6-azido-2-fluoropurine as a novel intermediate. In particular this invention pertains to a synthesis of fludarabine where the relatively low yield fluorination step is done before the costly coupling step.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

6-AZIDO-2-FLUOROPURINE**Background of the Invention**

This invention relates to a composition of matter and a
5 method for producing the same, and is particularly related to the
compound 6-azido-2-fluoropurine, useful in the synthesis of
fludarabine or fludarabine phosphate and related nucleoside
pharmacologic agents.

Fludarabine phosphate, also known as
10 9- β -D-arabinofuranosyl-2-fluoroadenine-5'-phosphate, is a prodrug
of the anti-cancer agent, 9- β -D-arabinofuranosyl-2-fluoroadenine.
Accordingly, fludarabine phosphate is a chemotherapeutically
effective form of the drug and is converted to the parent drug in
vivo. U.S. Pat. No. 4,210,745 discloses one method of synthesizing
15 the anti-cancer agent and U.S. Pat. No. 4,357,324 teaches the
phosphorylation of said agent to yield fludarabine phosphate. In
summary, fludarabine and fludarabine phosphate are commonly made
by the following process:

(a) acetylation: 2,6-diaminopurine (also referred to as
20 2-aminoadenine) in a mixture of pyridine and acetic anhydride is
refluxed to yield 2,6-diacetamidopurine, thus protecting the
amino groups with acetyl groups;

(b) coupling: 2,3,5-tri-O-benzyl-1-O-p-nitrobenzoyl-
D-arabinofuranose is converted to its corresponding chlorosugar
25 2,3,5-tri-O-benzyl-1-chloro- α -D-arabinofuranose, which is then

coupled with 2,6-diacetamidopurine in ethylene dichloride in the presence of molecular sieves for several days until all of the chlorosugar is consumed, to yield the protected nucleoside 2,6-diacetamido-9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)-
5 purine;

(c) deacetylation: the protected nucleoside is refluxed with methanolic sodium methoxide to remove the acetyl groups yielding the nucleoside 2-amino-9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)adenine;

10 (d) diazotization/fluorination: the protected nucleoside of step (c) undergoes diazotization and fluorination by reaction with sodium nitrite and fluoboric acid in a tetrahydrofuran-fluoboric acid (THF-HBF₄) system, to yield 9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)-2-fluoroadenine;

15 (e) debenzylation: the product from step (d) is treated with boron trichloride to remove the benzyl protecting groups; and lastly

(f) phosphorylation: the product from step (e) is mixed with phosphorous oxychloride in an alkyl phosphate followed by
20 hydrolysis in water, to yield 9- β -D-arabinofuranosyl-2-fluoroadenine-5'-phosphate, or fludarabine phosphate.

One of the disadvantages of this process is that the chlorosugar used in step (b) is very costly. Since the diazotization/fluorination reaction in step (d) has a relatively
25 low yield, much of the chlorosugar is similarly wasted.

SUBSTITUTE SHEET

Therefore, one way to improve this process is by introducing the 2-fluoro group before the coupling step. In this matter, the amount of chlorosugar needed for a given yield will be reduced. This invention provides one such means of improving the fludarabine synthesis, along with providing a more convergent synthesis of other nucleosides.


Summary of the Invention

This invention pertains to novel methods of synthesizing fludarabine, fludarabine phosphate and related nucleoside pharmacologic agents utilizing 6-azido-2-fluoropurine as a novel intermediate.

In particular, this invention pertains to a synthesis of fludarabine where the relatively low-yield fluorination step is done before the costly coupling step.

Detailed Description of the Invention


The novel compound of this invention is 6-azido-2-fluoropurine (3), which is synthesized by the following scheme. First, 2-amino-6-chloropurine (1) is heated with an alkali metal azide and a polar solvent to yield 2-amino-6-azidopurine (2):



SUBSTITUTE SHEET

Suitable alkali metal azides include lithium azide (LiN_3), sodium azide (NaN_3) and potassium azide (KN_3), with the preferred alkali metal azide being NaN_3 . The preferred solvent is aqueous dimethyl sulfoxide (DMSO). Reaction temperatures of 50-130°C are acceptable, however, 100-110°C is the preferred range. The reaction time may vary from 1 to 48 hours, however, the preferred time is 12-24 hours.

Second, compound (2) undergoes diazotization and fluorination reactions to yield the novel compound, 6-azido-2-fluoropurine (3):



Suitable media for carrying out the diazotization and fluorination reactions of this invention comprise a diazotization agent, one or more fluorination agents, and one or more polar solvents.

15 Suitable diazotization agents are nitrites, which include, without limitation, alkyl nitrites such as isobutyl-nitrite and, in particular, tertiary alkyl nitrites such as t-butylnitrile, and alkali metal nitrites such as sodium and potassium nitrite.


20 Suitable fluorination agents include, without
 limitation, hydrogen fluoride (HF) and fluoboric acid (HBF₄) or

salts thereof. The solvents can be anhydrous or aqueous and include, without limitation, water, pyridine and tetrahydrofuran (THF).

The preferred medium is an alkyl nitrite, aqueous
5 fluoboric acid and THF.

The reaction temperature may be varied over a wide range between -30°C and 60°C. Preferably the reaction is begun below 0°C and allowed to warm to ambient temperature over the course of 10 minutes to 3 hours and may be heated briefly to complete the reaction.

Azidopurine compounds such as (2) and (3) and their nucleoside derivatives can be represented by the general structure (A) wherein X is fluoro or amino and R is hydrogen or (protected)sugar. These compounds may exist in equilibrium with the corresponding tetrazolo-tautomer (B).




The ratio of tautomers (A) and (B) may depend on a number of factors such as the state of the sample (i.e., solid vs. solution), the nature of the solvent when the sample is in solution, the pH of the solution and on the identity of X.

SUBSTITUTE SHEET

Evidence of this equilibration of structures (A) and (B) may be seen by the spectroscopic techniques used for characterization of these compounds; however, it does not detract from the utility of these compounds as synthetic intermediates. For purposes of clarity, these compounds will be represented and identified as 6-azidopurine tautomer (A). This representation is intended to include any and all ratios of the tautomeric formulas (A) and (B) wherein X and R are as defined herein.

The novel compound of this invention, 6-azido-2-fluoropurine, finds particular usefulness in the synthesis of nucleosides such as fludarabine and its prodrug, fludarabine phosphate. This synthesis begins with coupling 6-azido-2-fluoropurine (3) with a protected chlorosugar 2,3,5-tri-O-benzyl-1-chloro- α -D-arabinofuranose (4) to yield 6-azido-2-fluoro-9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)purine (5), (Bn = benzyl group). The chlorosugar (4) is readily synthesized by the reaction described in Glaudemans et al., J. Org. Chem. 28:3004-3006 (1963),




which is incorporated herein by reference, and the best results are obtained with freshly prepared chlorosugar.

The coupling of (3) with (4) may be accomplished in a variety of solvents with the aid of suitable catalysts or reagents. For example, the reaction may be performed in a halocarbon solvent such as ethylene dichloride or dichloromethane or in polar aprotic solvents such as acetonitrile, or N,N-dimethylformamide (DMF) or in mixtures thereof, in the presence of a tertiary amino reagent such as

N,N-diisopropylethylamine. Molecular sieve may serve as a catalyst in these solvents in place of the tertiary amine. A hydride base such as sodium hydride may also be employed as a reagent; with a hydride base, however, polar aprotic solvents, or mixtures thereof, are preferred over halocarbon solvents.

Reaction temperatures of 0°C to 110°C may be employed. However, temperatures between 20°C and the reflux temperature of the solvent are preferred. Reaction times may vary from approximately 10 minutes to 7 days depending on the reaction temperature and on the catalyst or reagent used.


Catalytic hydrogenolysis of the protected nucleoside (5) reduces the azide to an amine and cleaves the O-benzyl groups to yield the nucleoside 9-β-D-arabinofuranosyl-2-fluoroadenine (6).



SUBSTITUTE SHEET

Preferably, this reaction is accomplished by conventional hydrogenation over a palladium catalyst in an alcoholic solvent. The results are generally improved by the addition of an acid catalyst such as aqueous hydrochloric acid to the reaction mixture. The required reaction time may vary from 1 hour to several days. Hydrogen pressures of 1 to 10 atmospheres (atm) are suitable, but the preferred pressure range is 2 to 5 atm.


Alternatively, in a more preferred process, the reduction of the azide to an amine and the removal of the benzyl protecting groups can be accomplished in separate steps. First, 6-azido-2-fluoro-9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)purine (5) is converted to 9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)-2-fluoroadenine (7) by reaction with a suitable reducing agent.



Without limitation, examples of suitable reducing reagents would include sodium borohydride or the combination of a dithiol and an amine such as 1,3-propanedithiol and triethylamine as described by Bayley et al., Tetrahedron Lett., pp. 3633-3364 (1978), which is incorporated herein by reference. With these reagents the

reaction is best performed in an alcoholic solvent such as methanol, ethanol or 2-propanol or a mixture of alcoholic solvents, but water or nonprotic solvents may be added if desired. This reaction proceeds at temperatures of 0-100°C; however, in the preferred process, the reaction is begun at ambient temperature and may be heated to 50° (or to the normal boiling point of the solvent being used. Next, (7) is converted to 9-β-D-arabinofuranosyl-2-fluoroadenine (6). The process for this conversion has been set forth in U.S. Pat. No. 4,210,745 which is incorporated herein by reference. The two-step process has the advantage that the sensitive intermediate (5) need not be isolated.

If desired, 9- β -D-arabinofuranosyl-2-fluoroadenine (6) can be phosphorylated to yield 9- β -D-arabinofuranosyl-2-fluoroadenine-5'-phosphate (8). This phosphorylation involves the reaction of 9- β -D-arabinofuranosyl-2-fluoroadenine with




phosphorous oxychloride in an alkyl phosphate, followed by hydrolysis in water, and can be done according to the method set

SUBSTITUTE SHEET

forth in U.S. Pat. No. 4,357,324, which is incorporated herein by reference.

In another embodiment, the novel compound of this invention (3) finds usefulness in the synthesis of

5 2-fluoroadenine (9):




Reduction of the azide (3) to form 2-fluoroadenine (9) can be accomplished in several ways depending upon the intended use of the product. If the main goal is to obtain a high yield of 2-fluoroadenine and sulfur containing impurities can be tolerated, the reaction can be done with a dithiol-amine mixture such as 1,3-propanedithiol and triethylamine. This reaction may be carried in an alcoholic solvent and nonprotic modifiers may be added; however, methanol is the preferred solvent because the product readily precipitates from the otherwise homogeneous mixture and is easily isolated by filtration. Temperatures of 0° to 100°C may be used; however, ambient temperature is preferred. The reaction is complete within minutes at this temperature; however, the best results are obtained when the mixture is allowed to stand for between 10 minutes and 4 hours to allow for complete precipitation of the product from solution.

SUBSTITUTE SHEET

Alternatively, if sulfur containing impurities cannot be tolerated, the reaction can be done with a hydride reducing agent such as sodium borohydride, as described hereinabove for the preparation of (7) from (5).

5 By either method, the product is easily isolated by filtration. These processes for the preparation of (9) have several advantages over methods previously described. Most importantly, the product is easily isolated in high purity by a simple filtration. The overall synthesis of 2-fluoroadenine (9)
10 from 2-amino-6-chloropurine proceeds in good yield and no chromatographic separations are required, thus the process is easily amenable to scale-up.

Reaction of (9) with chlorosugar (4) under conditions as described hereinabove for the coupling of (3) and (4) provides
15 an alternative process for the preparation of (7). This process is most preferred because the intermediate (7) is a solid and may be isolated by filtration after the coupling reaction.



2-Fluoroadenine finds additional utility in that it can be enzymatically converted to (6) as reported by Montgomery in

SUBSTITUTE SHEET

Nucleosides, Nucleotides and their Biological Applications, Rideout et al. eds., pp. 19-46 (1985), via the procedure of Krenitsky et al., Carbohydrate Research, 47:139-146 (1981).

Example 1
Synthesis of 2-Amino-6-azidopurine

5 A solution of sodium azide (14.08 g, 0.216 mol) in water (35 mL) was added to a solution of 2-amino-6-chloropurine (28.27 g, 0.166 mol) in dimethyl sulfoxide (DMSO, 280 mL). The mixture was heated at 100-110°C for 24 h, then the resulting suspension
10 was cooled and poured into 1.3 L of water. The precipitate was collected by filtration, washed with water and dried to afford . 26.11 g of 2-amino-6-azidopurine, mp >260°C; IR (KBr) 3313, 3146, 1678, 1641, 1551 cm⁻¹; ¹H NMR (DMSO-d₆, 360 MHz), δ 8.18 (s, 1H), 8.25 (bs, 2H), 13 (vbs, 1H); ¹³C NMR (DMSO-d₆, 90 MHz), 110.8,
15 138.7, 143.4, 145.7, 146.1 ppm.

Example 2
Synthesis of 6-Azido-2-fluoropurine

A solution of 2-amino-6-azidopurine (13.0 gm, 73.6 mmol) in tetrahydrofuran (THF, 163 mL), and 48% aqueous HBF₄ (42.24 mL)
20 was cooled in a bath at -20°C. A solution of t-butyl nitrite (12.65 mL) in THF (10 mL) was added over a 5-minute period. The bath was replaced with an ice-water bath for 30 minutes and then with a bath at 50°C for 15 minutes. The mixture was then poured over ice (600 g), and water (200 mL) was added. The suspension

was neutralized (pH 6-7) with saturated potassium carbonate (K_2CO_3), and ethyl acetate was added. The resulting solid potassium fluoborate (KBF_4) was collected by filtration and washed thoroughly with ethyl acetate. The aqueous layer was washed repeatedly with ethyl acetate and the combined ethyl acetate extracts were washed sequentially with water (500 mL) and saturated sodium chloride (NaCl) (250 mL) and dried over magnesium sulfate ($MgSO_4$) along with decolorizing carbon. The ethyl acetate was then filtered through celite and concentrated in vacuo to afford 9.36 g of the title compound. mp 190-195°C (d) (from ethyl acetate/pet. ether; the decomposition or melting point of this material varies from sample to sample); IR (KBr) 2240, 2200, 1620, 1595, 1565 cm^{-1} ; MS (EI⁺, m/z), 179 (M⁺, 55%), 151 ((M-N₂)⁺, 100%); ¹H NMR (DMSO-d₆, 360 MHz), δ 8.53 (s, 1H), 13.8 (bs, 1H); ¹³C NMR (DMSO-d₆, 90 MHz), 120 (very broad), 145.4 (broad), 152.2 (broad), 156 (very broad), 157.0 (d, J_{CF} = -210 Hz) ppm; UV (MeOH) λ_{max} , 250, 286 nm.

Example 3
Synthesis of 6-Azido-2-fluoro-
9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)purine

A solution of 2,3,5-tri-O-benzyl-1- α -D-arabinofuranosylchloride (freshly prepared from 1.9 g of 2,3,5-tri-O-benzyl-1-O-p-nitrobenzoyl-D-arabinofuranose), N,N-diisopropylethylamine (0.58 mL) and 6-azido-2-fluoropurine (0.50 g) in 10 mL of anhydrous 1,2-dichloroethane was heated at

reflux overnight. Additional N,N-diisopropylethylamine (0.26 mL) was added and heating was continued for an additional 24 hours. The mixture was cooled to ambient temperature and diluted with dichloromethane (60 mL) and washed sequentially with 10% aqueous sodium hydroxide (NaOH), water, 1N phosphoric acid (H_3PO_4), saturated NaCl and then dried over $MgSO_4$ along with decolorizing carbon. The dried solution was filtered through celite and concentrated in vacuo. The residue was purified by silica gel chromatography with gradient elution from 3:1 Hexane: ethyl acetate to 100% ethyl acetate to obtain 0.40 g of the title compound as a colorless oil; IR (neat) 3031, 2922, 2867, 2126; 1608 cm^{-1} ; 1H NMR ($DMSO-d_6$, 360 MHz), δ 3.65-3.75 (m, 2H), 4.16 (q, J = 5 Hz, 1H), 4.22 (d, J = 11.8 Hz), 4.42 (t, J = 5.5 Hz, 1H), 4.47 (d, J = 11.8 Hz, 1H), 4.51 (s, 2H), 4.58 (t, J = 5.5 Hz, 1H), 4.62 (d, J = 12.0 Hz, 1H), 4.68 (d, J = 12.0 Hz, 1H), 6.41 (d, J = 5.5 Hz, 1H), 6.9-6.95 (m, 2H), 7.1-7.2 (m, 3H), 7.25-7.4 (m, 10H), 8.48 (s, 1H); UV (MeOH) λ_{max} , 286 nm; MS (EI⁺, m/z) 582 (M+H)⁺.

Example 4

Synthesis of 9- β -D-Arabinofuranosyl-2-fluoroadenine

6-Azido-2-fluoro-9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)purine (0.19 g) was dissolved in 2-methoxyethanol (20 mL) with palladium (II) chloride ($PdCl_2$) (20 mg) and activated carbon and the mixture was hydrogenated at 55 pounds per square inch (psi) in a Parr shaker. The reaction was

monitored by thin layer chromatography (TLC) until complete. The mixture was then filtered through celite and the filtrate was concentrated in vacuo. Three times, the residue was dissolved in ethanol and reconcentrated. Then the residue was recrystallized from ethanol/water to obtain 0.063 g of the title compound which was consistent in its structure with an authentic sample by IR and TLC.

Example 5
Synthesis of 9-(2,3,5-Tri-O-benzyl-
 β -D-arabinofuranosyl)-2-fluoroadenine

6-Azido-2-fluoro-9-(2,3,5-tri-O-benzyl-
 β -D-arabinofuranosyl)purine (0.28 g, 0.48 Mmol) was dissolved in warm 2-propanol (3 mL) and then cooled to about 25°C. To the resulting solution was added sodium borohydride (18 mg, 0.48 Mmol) and the mixture was stirred at room temperature for 10 minutes and then at reflux for 15 minutes. The reaction was complete as determined by TLC so it was cooled to room temperature and diluted with water (10 mL). The resulting precipitate was recovered by filtration to obtain 0.19 g of the title compound; mp 159-161°C (from toluene/ethanol). This material was identical by IR and TLC with an authentic sample of the title compound.

Example 6
Synthesis of 9- β -D-Arabinofuranosyl-2-fluoroadenine

A solution of 2,3,5-tri-O-benzyl-
1- α -D-arabinofuranosylchloride (freshly prepared from 1.9 g of

2,3,5-tri-O-benzyl-1-O-p-nitrobenzoyl-D-arabinofuranose) and 6-azido-2-fluoropurine (0.50 g) in anhydrous acetonitrile (30 mL) was stirred for 1 hour at room temperature and then 3 Å molecular sieve (1.26 g, pellets) was added. The mixture was stirred under an inert atmosphere for 3 days and then filtered. The filtrate was concentrated under reduced pressure and the residue was dissolved in 2-propanol and methanol, and then sodium borohydride (0.13 g) was added. After stirring overnight at room temperature, the resulting precipitate was collected by filtration. The precipitate was washed with 2-propanol followed by boiling water and then dried to obtain 0.14 g of the title compound. The organic filtrates were concentrated under reduced pressure and the residue was partitioned between dichloromethane and water. The dichloromethane solution was dried over $MgSO_4$ and then filtered and placed on a silica gel column. Elution with 1% methanol in dichloromethane provided an additional 0.10 g of the title compound. Both samples were identical by IR and TLC to an authentic sample of the title compound.

Example 7

Synthesis of 2-Fluoroadenine

Triethylamine (0.40 mL) was added via syringe to a solution of 6-azido-2-fluoropurine (0.256 g) and 1,3-propanedithiol (0.29 mL) in methanol (13.5 mL). After 15 minutes, the reaction was complete as judged by TLC and a white precipitate had formed. The precipitate was collected by

filtration and washed with two 10 mL portions of methanol and then dried to obtain 0.203 g of 2-fluoroadenine, mp >300°C. This material was identical to an authentic sample by TLC, NMR and IR.

Example 8
Synthesis of 2-Fluoroadenine

5 A sample of 6-azido-2-fluoropurine (0.18 g) was dissolved in warm 2-propanol (3 mL) and then cooled to ambient temperature. Sodium borohydride (38 mg) was added in small portions. The vigorous gas evolution was allowed to subside
10 between additions. After the addition was complete, the mixture was stirred at ambient temperature and then was heated at 72°C for 1.5 h. The mixture was then cooled to ambient temperature and diluted with water (10 mL) and the pH was adjusted to 6-7 with 1N hydrochloric acid (HCl) and saturated K₂CO₃ and then the
15 mixture was concentrated to dryness under vacuum. The residue was triturated in 20 mL of hot water then allowed to cool to ambient temperature. The precipitate was collected by filtration, washed with water and dried to obtain 0.08 g of the title compound as an off-white solid, mp >300°C. This material
20 was identical to an authentic sample by TLC, and IR.

Example 9
Synthesis of 9-(2,3,5-Tri-O-benzyl-
β-D-Arabinofuranosyl)-2-fluoroadenine

A mixture of 2-fluoroadenine (0.50 g), 2,3,5-tri-
25 O-benzyl-1-α-D-arabinofuranosyl chloride (freshly prepared from


2.22 g of 2,3,5-Tri-O-benzyl-1-O-p-nitrobenzoyl-D-arabinofuranose) and N,N-diisopropylethylamine (0.56 mL) in anhydrous N,N-dimethylformamide (10 mL) was stirred at ambient temperature for 3 days under a nitrogen atmosphere. The mixture
5 was then concentrated under high vacuum and the residue was partitioned between dichloromethane (200 mL) and water (25 mL). The organic phase was washed sequentially with saturated NaCl (50 mL), 1M H₃PO₄ (50 mL) and saturated NaCl (25 mL), and was then dried over MgSO₄ and decolorizing carbon. The dried solution was
10 filtered and concentrated under vacuum. The residue was purified by silica gel chromatography with 1% methanol in dichloromethane as eluent. The appropriate fractions were combined and recrystallized from ethanol/toluene to obtain 0.39 g of the title compound. This material was identical by IR and TLC with an
15 authentic sample.

This invention has been described in particular reference to certain preferred embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention.

Claims

We claim:

1. A compound 6-azido-2-fluoropurine, with the structure:



2. A method for preparing 6-azido-2-fluoropurine comprising the following steps:

(a) reacting 2-amino-6-chloropurine with an alkali metal azide to yield 2-amino-6-azidopurine; and

(b) diazotizing and fluorinating 2-amino-6-azidopurine to yield 6-azido-2-fluoropurine.

3. A method for preparing fludarabine phosphate comprising the following steps:

(a) reacting 2-amino-6-chloropurine with an alkali metal azide to yield 2-amino-6-azidopurine;

(b) diazotizing and fluorinating 2-amino-6-azidopurine to yield 6-azido-2-fluoropurine;

(c) coupling said 6-azido-2-fluoropurine with a chlorosugar to yield 6-azido-2-fluoro-9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)purine;

(d) converting 6-azido-2-fluoro-9-(2,3,5-tri-O-benzyl-

β -D-arabinofuranosyl)purine to 9- β -D-arabinofuranosyl-2-fluoroadenine; and

(e) phosphorylating 9- β -D-arabinofuranosyl-2-fluoroadenine to yield fludarabine phosphate.

5 4. The method of claim 3 wherein step (d) comprises catalytic hydrogenolysis of 6-azido-2-fluoro-9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)purine to yield 9- β -D-arabinofuranosyl-2-fluoroadenine in a single step.

10 5. The method of claim 3 wherein step (d) comprises first converting 6-azido-2-fluoro-9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)purine to 9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)-2-fluoroadenine followed by converting 9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)-2-fluoroadenine to 9- β -D-arabinofuranosyl-2-fluoroadenine.

15 6. A method for preparing 2-fluoroadenine comprising the following steps:

(a) reacting 2-amino-6-chloropurine with an alkali metal azide to yield 2-amino-6-azidopurine;

20 (b) diazotizing and fluorinating 2-amino-6-azidopurine to yield 6-azido-2-fluoropurine; and

(c) reducing 6-azido-2-fluoropurine to yield 2-fluoroadenine.

7. The method of claim 6 wherein step (c) comprises reaction with a dithiol-amine mixture.

8. The method of claim 6 wherein step (c) comprises reaction with a hydride reducing agent.

5 9. A method for preparing fludarabine phosphate which comprises:

(a) reacting 2-amino-6-chloropurine with an alkali metal azide to yield 2-amino-6-azidopurine;

10 (b) diazotizing and fluorinating 2-amino-6-azidopurine to yield 6-azido-2-fluoropurine;

(c) reducing 6-azido-2-fluoropurine to yield 2-fluoroadenine;

(d) coupling 2-fluoroadenine with a chlorosugar to yield 9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)-2-fluoroadenine;

15 (e) converting 9-(2,3,5-tri-O-benzyl- β -D-arabinofuranosyl)-2-fluoroadenine to 9- β -D-arabinofuranosyl-2-fluoroadenine; and

(f) phosphorylating 9- β -D-arabinofuranosyl-2-fluoroadenine to yield fludarabine phosphate.

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/US91/08838

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C07D 473/40; C07H 19/20 US CL : 544/277; 536/27		
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁴</div> <div style="display: flex; justify-content: space-between;"> Classification System : Classification Symbols </div> <div style="margin-top: 10px;"> US CL 544/277; 536/27; 536/26 </div> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁵</div> <div style="margin-top: 10px;"> STN (CHEMICAL ABSTRACTS) COMPUTER SEARCH </div>		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁵
A	US,A 4,188,378 (Montgomery) 12 February 1980 Whole document	1-9
Y	US,A 4,199,574 (Schaeffer) 22 April 1980 Whole Document	1-9
A	US,A 4,210,745 (Montgomery) 01 July 1980 Whole document	1-9
A	US,A 4,357,324 (Montgomery, et al.) 02 November 1982 Whole document	1-9
A	US,A 4,609,661 (Verheyden, et al.) 02 September 1986 Whole document	1-9
A	US,A 4,963,661 (Matthes, et al) 16 October 1990 Whole document	1-9
Y	US,A 4,968,674 (Taniyama, et al) 06 November 1990 Whole document	1-9
Y,P	JP,A 47-47,399 (Fujisawa Pharm. Co.) 29 November 1972 Whole document	1-9
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁸ Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ² <div style="text-align: center; font-size: 1.2em;">12 March 1992</div>	Date of Mailing of this International Search Report ³ <div style="text-align: center; font-size: 1.5em;">12 MAY 1992</div>	
International Searching Authority ¹ <div style="text-align: center;">ISA/US</div>	Signature of Authorized Officer ¹⁰ <div style="text-align: center;"> Diana Rivers, Primary Examiner </div>	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	Journal of the American Chemical Society, vol. 82, issued 1960, Montgomery, et al. "Synthesis of Potential Anticancer Agents. XX. 2-Fluoro-purines", pages 463-468.	1-9
A	Journal of Organic Chemistry, vol. 28, issued 1963, Claudemans, et al., "Syntheses with Partially Benzylated Sugars. III. A Simple Pathway to a ' <u>cis</u> Nucleoside', 9-B-D- Arabinofuranosyladenine (Spongoadenosine)", pages 3004-3006.	1-9
Y	Journal of Organic Chemistry, vol. 31, issued 1966, Temple, et al., "Studies on the Azidoazomethine-Tetrazole Equilibrium. V. 2-and 6-Azidopurines"	1-9

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority does not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
	pages 2210-2215	
Y	Journal of Organic Chemistry, vol. 34, no. 5, issued 1969, Eaton, et al., "Convenient Synthesis of 2-Fluoroadenine", pages 747-748.	1-9
A	Journal of Organic Chemistry, vol. 44, no. 22, issued 1979, Olah, et al., "Synthetic Methods Methods and Reactions, 63. Pyridinium Poly (hydrogen fluoride) (30% Pyridine-70% Hydrogen Fluoride): A convenient Reagent for Organic Fluorination Reactions", pages 3872-3881.	1-9
A	Biochemical Pharmacology, vol. 30, no. 19, issued 1981, Great Britain, Huagn, et al., "Analogues of 2'-Deoxyadenosine: Facile Enzymatic Preparation and Growth Inhibitory Effects on Human Cell Lines", pages 2663-2671.	1-9
A	Journal of Heterocyclic Chemistry, vol. 20, issued 1983, LaMontagne, et al. "Preparation of 7-Substituted Pyrrolo [2,3-d] pyrimidines and 9-Substituted Purines as Potential Antiparasitic Agents" pages 295-299.	1-9
A	CAN. J. Chem. vol. 59, issued 1981, Robins et al, "Nucleic acid related compounds. 34. Non-aqueous diazotization with tert-butyl nitrite. Introduction of fluorine, chlorine, and bromine at C-2 of purine nucleosides" pages 2608-2611.	1-9